Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Oo

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of the American Geriatrics Society|October 18, 2002
Change in creatinine clearance with advancing ageCharles Oo, Baolin Liu, George Hill
Drug Discovery Today|November 18, 2017
Fixed-dose combinations: a potential means to boost drug development for selected drugsCharles Oo, Sherwin K B Sy
Journal of Clinical Pharmacology|July 3, 2026
FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future DirectionsCharles Oo, Xiaofa Qin, Sherwin Kb Sy
British Journal of Clinical Pharmacology|October 24, 2002
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacidsPaul Snell, Charles Oo, Al Dorr, et al.
Clinical Drug Investigation|May 23, 2007
Oseltamivir distributes to influenza virus replication sites in the middle ear and sinusesMichael Kurowski, Charles Oo, Hugh Wiltshire, et al.
Drug Discovery Today|June 25, 2023
Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?Charles Oo, Xiaoping Zhang, Sherwin K B Sy
Drug Discovery Today|April 4, 2015
There is no better time than the present: nanotechnology as a disruptive innovation for drug developmentCharles Oo, Jui-Chen Tsai, H Danny Kao
Frontiers in Pharmacology|June 29, 2026
Editorial: New drugs and future challenges in drug metabolism and transportMaja Đanić, Charles Oo, Xue Li, et al.
Drug Discovery Today|November 7, 2025
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?Charles Oo, Joanna M Sadowska, Sherwin K B Sy
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 6, 2013
In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liverYoshiyuki Igawa, Tomomichi Fujitani, Bharti Shah, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of the American Geriatrics Society|October 18, 2002
Change in creatinine clearance with advancing ageCharles Oo, Baolin Liu, George Hill
Drug Discovery Today|November 18, 2017
Fixed-dose combinations: a potential means to boost drug development for selected drugsCharles Oo, Sherwin K B Sy
Journal of Clinical Pharmacology|July 3, 2026
FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future DirectionsCharles Oo, Xiaofa Qin, Sherwin Kb Sy
British Journal of Clinical Pharmacology|October 24, 2002
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacidsPaul Snell, Charles Oo, Al Dorr, et al.
Clinical Drug Investigation|May 23, 2007
Oseltamivir distributes to influenza virus replication sites in the middle ear and sinusesMichael Kurowski, Charles Oo, Hugh Wiltshire, et al.
Drug Discovery Today|June 25, 2023
Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?Charles Oo, Xiaoping Zhang, Sherwin K B Sy
Drug Discovery Today|April 4, 2015
There is no better time than the present: nanotechnology as a disruptive innovation for drug developmentCharles Oo, Jui-Chen Tsai, H Danny Kao
Frontiers in Pharmacology|June 29, 2026
Editorial: New drugs and future challenges in drug metabolism and transportMaja Đanić, Charles Oo, Xue Li, et al.
Drug Discovery Today|November 7, 2025
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?Charles Oo, Joanna M Sadowska, Sherwin K B Sy
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 6, 2013
In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liverYoshiyuki Igawa, Tomomichi Fujitani, Bharti Shah, et al.
Pageof 4